EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors

Lilia Cinti, Lucrezia Tuosto, Piergiorgio Roberto iD, Roberta Campagna, Aurelia Rughetti, Chiara Napoletano, Alain J Gelibter, Daniele Santini, Guido Antonelli, Ombretta Turriziani

PLOS One · 15.05.2026 · 21 (5) · e0349500

DOI: 10.1371/journal.pone.0349500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 15.05.2026. Verfasst von Lilia Cinti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Laboratory of Microbiology and Virology, Sapienza University o f Rome, Rome, Italy. Hauptthemen laut MEDLINE: Torque teno virus, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Istituto Superiore di SanitÃ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, Torquetenovirus (TTV) load has emerged as a potential biomarker of immune competence across various clinical contexts, albeit its significance in cancer patients undergoing immunotherapy remains largely unexplored. This study aimed to investigate the level of TTV viral load in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). A total of 64 NSCLC patients were enrolled. Serum TTV DNA levels were quantified by real-time PCR at baseline (T0) and after three months of ICI therapy (T1). As control, TTV levels were also measured in a cohort of healthy donors at a single time point. Statistical analyses were performed to compare TTV copy numbers across groups and time points. At baseline, cancer patients exhibited significantly higher TTV viral loads than healthy donors, consistent with an immunocompromised status. Following ICI treatment, a significant decline in TTV levels was observed in the oncologic cohort, reaching values comparable to those of healthy individuals, with a more pronounced decrease observed in patients responsive to therapy. This study provides the first evidence that TTV viral load decreases following immunotherapy in NSCLC patients, potentially reflecting a restoration of immune competence. These findings support the hypothesis that TTV monitoring could serve as a surrogate marker of immune function during ICI treatment. Further large-scale, longitudinal studies are warranted to validate its clinical meaning in oncologic settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Torque teno virusCarcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsDNA, ViralViral LoadBiomarkersRetrospective StudiesHumansMaleFemaleMiddle AgedAgedCase-Control Studies

Substanzen

Immune Checkpoint InhibitorsBiomarkersDNA, Viral

Autor:innen und Institutionen

  • Department of Molecular Medicine, Laboratory of Microbiology and Virology, Sapienza University o f Rome, Rome, Italy.
  • Department of Medical Biotechnologies, PhD of National Interest in Innovation in the Diagnosis, Prevention and Treatment of Infections at Epidemic-Pandemic Risk, University of Siena, Siena, Italy.
  • University Hospital "Policlinico Umberto I", Rome, Italy.
  • Department of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapies, Sapienza University of Rome, Rome, Italy.
  • Phd of Network Oncology and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of Public Health, PhD National Programme in One Health approaches to Infectious Diseases and Life Science Research, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.

ORCID-Profile: Piergiorgio Roberto

Förderung

  • Ministero dell'Università e della Ricerca
  • Istituto Superiore di SanitÃ

Zitieren

APA

Cinti, L., Tuosto, L., Roberto, P., Campagna, R., Rughetti, A., Napoletano, C., Gelibter, A. J., Santini, D., Antonelli, G., & Turriziani, O. (2026). Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors. PLOS One, 21(5), e0349500. https://doi.org/10.1371/journal.pone.0349500

Vancouver

Cinti L, Tuosto L, Roberto P, Campagna R, Rughetti A, Napoletano C, et al. Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors. PLOS One. 2026;21(5):e0349500. doi:10.1371/journal.pone.0349500

BibTeX
@article{Cinti2026,
  author = {Cinti, Lilia and Tuosto, Lucrezia and Roberto, Piergiorgio and Campagna, Roberta and Rughetti, Aurelia and Napoletano, Chiara and Gelibter, Alain J and Santini, Daniele and Antonelli, Guido and Turriziani, Ombretta},
  title = {Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {e0349500},
  doi = {10.1371/journal.pone.0349500}
}
Kostenlos starten →